ANGLE PLC's (LON:AGL) (OTCQX:ANPCY) Andrew Newland speaks to Proactive to update on progress since the COVID-19 lockdown began.
He says a key focus during the period has been on finalising the significant amount of written documentation and analysis for the firm’s imminent submission to the US Food & Drug Administration.
Newland also discusses how he believes its ground-breaking liquid biopsy system could have a role to play helping guide trials in cancer immunotherapies.
